Spectrum Pharmaceuticals sells marketed portfolio to Acrotech Biopharma
Spectrum Pharma announced an agreement to sell its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma, a subsidiary of Aurobindo Pharma USA. Spectrum will receive $160 million in an upfront cash payment and up to $140 million in regulatory and sales-based milestones January 17, 2019